These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38865086)

  • 1. Empagliflozin in the treatment of heart failure.
    Shafiq A; Hameed I; Biegus J; Fudim M; Khan MS
    Future Cardiol; 2024 Apr; 20(5-6):251-261. PubMed ID: 38865086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.
    Hernandez AF; Udell JA; Jones WS; Anker SD; Petrie MC; Harrington J; Mattheus M; Seide S; Zwiener I; Amir O; Bahit MC; Bauersachs J; Bayes-Genis A; Chen Y; Chopra VK; A Figtree G; Ge J; G Goodman S; Gotcheva N; Goto S; Gasior T; Jamal W; Januzzi JL; Jeong MH; Lopatin Y; Lopes RD; Merkely B; Parikh PB; Parkhomenko A; Ponikowski P; Rossello X; Schou M; Simic D; Steg PG; Szachniewicz J; van der Meer P; Vinereanu D; Zieroth S; Brueckmann M; Sumin M; Bhatt DL; Butler J
    Circulation; 2024 May; 149(21):1627-1638. PubMed ID: 38581389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.
    Wanner C; Iliev H; Duarte N; Schueler E; Soares AR; Thanam V; Pfarr E
    Adv Ther; 2024 Jul; 41(7):2826-2844. PubMed ID: 38771475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
    Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
    Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
    Udell JA; Petrie MC; Jones WS; Anker SD; Harrington J; Mattheus M; Seide S; Amir O; Bahit MC; Bauersachs J; Bayes-Genis A; Chen Y; Chopra VK; Figtree G; Ge J; Goodman SG; Gotcheva N; Goto S; Gasior T; Jamal W; Januzzi JL; Jeong MH; Lopatin Y; Lopes RD; Merkely B; Martinez-Traba M; Parikh PB; Parkhomenko A; Ponikowski P; Rossello X; Schou M; Simic D; Steg PG; Szachniewicz J; van der Meer P; Vinereanu D; Zieroth S; Brueckmann M; Sumin M; Bhatt DL; Hernandez AF; Butler J
    J Am Coll Cardiol; 2024 Jun; 83(23):2233-2246. PubMed ID: 38588929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Anker SD; Butler J; Filippatos G; Khan MS; Marx N; Lam CSP; Schnaidt S; Ofstad AP; Brueckmann M; Jamal W; Bocchi EA; Ponikowski P; Perrone SV; Januzzi JL; Verma S; Böhm M; Ferreira JP; Pocock SJ; Zannad F; Packer M
    Circulation; 2021 Jan; 143(4):337-349. PubMed ID: 33175585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
    Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M
    Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
    Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
    Levine MJ
    Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
    Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.
    Böhm M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Mahfoud F; Brueckmann M; Jamal W; Ofstad AP; Schüler E; Ponikowski P; Wanner C; Zannad F; Packer M;
    J Am Coll Cardiol; 2021 Sep; 78(13):1337-1348. PubMed ID: 34556320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
    JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
    Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
    Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
    Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes.
    Kräker K; Herse F; Golic M; Reichhart N; Crespo-Garcia S; Strauß O; Grune J; Kintscher U; Ebrahim M; Bader M; Alenina N; Heuser A; Luft FC; Müller DN; Dechend R; Haase N
    Sci Rep; 2020 Aug; 10(1):14061. PubMed ID: 32820187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.